Latest News and Press Releases

Science 37 announces the successful completion of its third FDA inspection with a No Action Indicated (NAI) categorization.

Science 37 announces the successful completion of its second FDA inspection, reaffirming the quality of its Direct-to-Patient Site for clinical research.

Science 37 contributes almost half (47%) of the U.S. enrollment for GSK Phase 3 rare disease study while bolstering participant retention figures.

Science 37 enrolls 65 patients per month for its sponsor's Phase 3 infectious disease clinical trial.

Nearly 20 studies have successfully leveraged Science 37's medical and operational expertise to boost patient recruitment and enrollment activities.

Science 37 Holdings, Inc. today announced the preliminary outcome of its recent FDA Inspection focusing on critical areas and documentation.

Science 37's Patient Recruitment Solution provides fully-consented patients to clinical trial sites to supplement enrollment.